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Milk Fat Globule-Epidermal Growth Factor-Factor 8 (MFG-E8) as a Novel
Biomarker for Periodontal Disease
Abstract
AIM:
To detect the presence of milk fat globule-epidermal growth factor-factor 8 (MFG-E8) in human gingival
crevicular fluid (GCF) and to determine its potential role as a biomarker for periodontal disease activity.
MATERIALS & METHODS:
GCF was collected from a total of 230 sites from with seven subjects with gingivitis, twelve subjects with
chronic moderate periodontitis, fourteen subjects with chronic severe periodontitis, six subjects with
localized severe periodontitis as well as seven clinically healthy subjects. Subjects from the severe
periodontitis group received nonsurgical therapy and were re-evaluated after 4 weeks. GCF was recollected from thirty sites in five subjects at that point. Pocket reduction surgery was performed on the
same subgroup and GCF was collected again at the 4-month postoperative appointment. GCF collection
was performed using paper strips and analyzed for the presence of MFG-E8 and cytokines using
multiplexing magnetic bead immunoassays (Luminex xMAP with MagPlex beads). Each sample was
tested using an MFG- E8 kit, a human cytokine/chemokine kit and a human bone panel kit.
RESULTS:
MFG-E8 was detected at higher levels in sites with gingivitis and gingival health as compared to all
periodontitis groups, suggesting that MFG-E8 production is down regulated in periodontitis. Consistent
with this notion, MFG-E8 was found to significantly increase following non-surgical therapy of subjects
with severe periodontitis. Furthermore, the levels of MFG-E8 significantly increased after surgical
treatment correlating with decreased probing pocket depths. IL-1α, IL-1β, RANKL, OPG, IL-6 and IL-17A
were detected at levels consistent with those found in earlier studies. In the periodontitis treatment
subgroup, the levels of RANKL, IL-6 and IL-17A decreased with decreasing probing pocket depths.
CONCLUSIONS:
MFG-E8 was detected in human GCF collected from healthy, gingivitis and periodontitis subjects using a
magnetic bead-based immunoassay. The levels of MFG-E8 were negatively related to the level of gingival
inflammation and increased after both non-surgical and surgical treatment of periodontal disease. These
data suggest the potential of MFG-E8 as a novel biomarker of periodontal disease.
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ABSTRACT

AIM:
To detect the presence of milk fat globule-epidermal growth factor-factor 8 (MFG-E8) in
human gingival crevicular fluid (GCF) and to determine its potential role as a biomarker for
periodontal disease activity.
MATERIALS & METHODS:
GCF was collected from a total of 230 sites from with seven subjects with gingivitis,
twelve subjects with chronic moderate periodontitis, fourteen subjects with chronic severe
periodontitis, six subjects with localized severe periodontitis as well as seven clinically healthy
subjects. Subjects from the severe periodontitis group received nonsurgical therapy and were reevaluated after 4 weeks. GCF was re-collected from thirty sites in five subjects at that point.
Pocket reduction surgery was performed on the same subgroup and GCF was collected again at
the 4-month postoperative appointment. GCF collection was performed using paper strips and
analyzed for the presence of MFG-E8 and cytokines using multiplexing magnetic bead
immunoassays (Luminex xMAP with MagPlex beads). Each sample was tested using an MFGE8 kit, a human cytokine/chemokine kit and a human bone panel kit.
RESULTS:
MFG-E8 was detected at higher levels in sites with gingivitis and gingival health as
compared to all periodontitis groups, suggesting that MFG-E8 production is down regulated in
periodontitis. Consistent with this notion, MFG-E8 was found to significantly increase following
non-surgical therapy of subjects with severe periodontitis. Furthermore, the levels of MFG-E8
significantly increased after surgical treatment correlating with decreased probing pocket depths.
IL-1α, IL-1β, RANKL, OPG, IL-6 and IL-17A were detected at levels consistent with those
found in earlier studies. In the periodontitis treatment subgroup, the levels of RANKL, IL-6 and
IL-17A decreased with decreasing probing pocket depths.
CONCLUSIONS:
MFG-E8 was detected in human GCF collected from healthy, gingivitis and periodontitis
subjects using a magnetic bead-based immunoassay. The levels of MFG-E8 were negatively
related to the level of gingival inflammation and increased after both non-surgical and surgical
treatment of periodontal disease. These data suggest the potential of MFG-E8 as a novel
biomarker of periodontal disease.
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Milk Fat Globule-Epidermal Growth Factor-Factor 8 (MFG-E8) as a Novel
Biomarker for Periodontal Disease

INTRODUCTION

Periodontal Disease
Dental plaque accumulation can lead to inflammation in the gingival tissues leading to
gingivitis. In some susceptible individuals, gingival inflammation may progress and involve the
alveolar bone and other tooth supporting structures leading to periodontitis [1].
Gingivitis is characterized by inflammation which is limited to the gingival tissues
without affecting the attachment levels of the teeth. The main etiology for this gingival
inflammation is the microbial biofilm that accumulates on the dental structures especially with
the lack of proper oral hygiene practices [2]. This was proven by the classic 1965 study by Loë
[2] where subjects with good biofilm control developed gingivitis 10-21 days after abstaining
from oral hygiene practices. Resolution of gingival inflammation was noted in the same subjects
within one week of resuming oral hygiene practices which shows a direct relationship between
microbial biofilm and gingivitis.
Periodontitis compromises the integrity of the periodontium, i.e., the tooth-supporting
structures such as the gingiva, periodontal ligament, and the alveolar bone. The disease is
initiated by inflammation caused by dysbiotic bacterial communities forming on subgingival
tooth sites [3]. It is broadly classified as being either chronic or aggressive [4]. Aggressive
periodontitis differs from chronic periodontitis in the rapid rate of bone and attachment loss is
subjects who are generally healthy, as well as having a tendency for familial aggregation [5].
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Historically, it was accepted that periodontitis occurs as a continuation of gingival
inflammation [6, 7]. In 1986, Loë published the results of a 15-year cohort study of Sri Lankan
tea workers. The cohort consisted of a group of male tea workers aged between 14 and 30 years
with no access to dental care. At the 15-year follow up, it was found that around 8% of the
subjects had “rapidly progressing disease”, or what would be described today as aggressive
periodontitis; 81% of the subjects were described as having “moderately progressing disease”
while around 11% had no progression of periodontal disease [8]. This led to the conclusion that
only a subset of the population are susceptible to periodontal disease progression and that
periodontitis does not necessarily occur as a continuation of gingivitis.
Many studies have been done to allow further understanding of the host’s immune
response and its role in detecting individuals who are susceptible to periodontal disease
progression. Overall, periodontal disease susceptibility is determined by genetic factors that
predispose to hyperinflammatory responses or by environmental factors (e.g., diet and stress) and
risk-related behavior (e.g., smoking) that can modify the host immune response in a destructive
direction. Further understanding of the role of the host’s immune response to periodontal
pathogens may allow development of new host modulatory therapies that aim to treat periodontal
disease by targeting specific aspects of the host immune system. These therapies differ from the
current periodontal treatment modalities which focus on treating the local, mostly microbial
etiological factors [9].
Recent microbiome analyses of human dental plaque and animal model-based
mechanistic studies collectively suggest that the pathogenesis of periodontitis is not caused by
individual bacteria often referred to as “periopathogens” but rather involves polymicrobial
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synergy and dysbiosis, that is, an elevation of certain populations in the oral bacterial community
that synergistically lead to destructive inflammatory responses and bone loss [10].
Cytokines are key mediators of the host response and play a major role in the
pathogenesis of periodontal disease [11]. Cytokines are proteins that are involved in immune
regulation and the inflammatory response. Graves in 2008 classified cytokines that are involved
in the stimulation of inflammatory reactions as chemokines, innate immune cytokines and
acquired immune cytokines [11].
Many pro- and anti-inflammatory cytokines have been studied in relation to periodontal
disease. The initial immune response was characterized by the increase in protective antiinflammatory cytokines such as transforming growth factor-β (TGF-β), interleukin-4 (IL-4) and
IL-10 [9, 12]. As periodontal disease progresses, the cytokine profile shows a shift from antiinflammatory to pro-inflammatory cytokines such as IL-1, IL-6, tumor necrosis factor-α (TNFα), prostaglandin E2 (PGE2) and other mediators such as matrix metalloproteinases (MMPs).
The increase of pro-inflammatory mediators leads to periodontal tissue breakdown and bone loss
leading to apical migration of the dental supporting structures and clinical attachment loss [13].
Periodontitis is typically diagnosed based on clinical and radiographic evaluation of the
resulting alveolar bone destruction and clinical attachment loss by manual measuring of probing
pocket depths (PPD), bleeding on probing (BOP), and radiographic bone levels [14]. These
parameters give information about the history of periodontal infection in an individual but do not
necessarily give information about the current activity or future disease progression [15]. The
increasing knowledge about the host’s response in various stages of periodontal disease may
allow the future development of more accurate diagnostic methods as well as the potential
development of new therapeutics that target the host’s immune response.
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Gingival Crevicular Fluid
Gingival crevicular fluid (GCF) is a secreted fluid which is naturally found in gingival
tissues. It is believed that in healthy gingival tissues, a transudate of interstitial fluid is secreted
into the gingival sulcus [16]. As inflammation occurs in gingival tissue, an increased
permeability of gingival microvascular structures is seen which leads to the secretion of an
inflammatory exudate, which explains the increase GCF volume with increasing gingival
inflammation [17-19].
The earliest published reports about the presence of secretions from the gingival fluid are
found in the early 1950s studies of gingival pockets by Waerhaug [20, 21]. In 1958, the presence
of gingival fluid was found accidentally by Brill and Krasse [22]. In their study, which was
initially conducted to examine the gingival microflora in dogs, iodine solution was used to
disinfect the teeth before sample collection and it was noted that the iodine rapidly disappeared
from the gingival pockets. Also, fluorescein dye was intravenously injected as part of a study and
within 30 seconds, they found that the dye was detected in the healthy gingiva of the animals and
could be retrieved on filter paper strips [23]. This discovery of gingival fluid secretion led to
further studies by Brill. In 1959, Brill and Bjorn showed the presence of gingival fluid secretions
in humans with healthy gingival tissues [24]. Brill also showed that the fluid secretion is affected
by chewing and brushing and that the fluid is related to vascular permeability.
GCF has been used as a medium to detect various cells and molecules which are related
to periodontal pathophysiology including the different biomarkers associated with the
periodontal inflammatory process.
Masada found that IL-1 was expressed in the majority of GCF samples they tested [25].
Their samples were taken from subjects with moderate to severe periodontal disease and subjects
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with “early-onset periodontitis” or aggressive periodontitis. They also showed significant
reduction of IL-1 levels in most sites with aggressive periodontitis after non-surgical periodontal
therapy. In 1992 and 1993, Wilton detected IL-1β in GCF in 68.9% of sites with chronic
periodontitis in one sample population and in 88.6% of sites with chronic periodontitis tested in
another sample population [26, 27].
Hou studied the levels of IL-1β in GCF following phase I therapy. It was found that the
GCF levels of IL-1β were reduced at the reevaluation appointment following non-surgical
therapy[28].
Geivelis followed 5 subjects on periodontal maintenance for 6 months. GCF samples
were taken initially prior to non-surgical therapy followed by samples after 3 months and 6
months [29]. IL-6 in GCF showed positive correlation with inflammation as manifested
clinically by increased probing depths and bleeding upon probing. It was also found that IL-6
levels in GCF was increased in sites with progressive periodontal breakdown as compared to
inactive sites.
Mogi also reported the levels of IL-6 in GCF in subjects with periodontitis along with
levels of IL- 1β, β2-microglobulin (B2-MG), interferon-γ (IFN-γ) and transforming growth
factor-α (TGF-α) [30]. The sample groups were healthy periodontal sites as controls and sites
with mild and severe periodontitis. It was found that the levels of IL-6 increased 3 times in cases
of severe periodontitis as compared to healthy controls. The levels of IL-1β and B2-MG were
also significantly increased in periodontitis. IFN-γ was increased in periodontitis but the increase
was not statistically significant. TGF-α, on the other hand, had a statistically significant decrease
in cases with mild and severe periodontitis cases as compared to healthy sites.
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Gamonal evaluated GCF IL-1β, IL-8 chemokine, RANTES and IL-10 after provision of
periodontal therapy in the previous study. The study enrolled 12 subjects with moderate-severe
periodontitis and 6 periodontally healthy subjects as controls. GCF was collected from all
subjects at baseline and was also collected 2 months after periodontal therapy in six subjects who
received non-surgical periodontal treatment. IL-8, IL-1β and RANTES were detected in GCF
from most sites in periodontitis subjects and that all tested cytokines were reduced in subjects
who received periodontal therapy. Subjects with periodontitis also showed significantly higher
GCF volume when compared to controls and that volume was reduced following periodontal
therapy [31].
Vernal used ELISA to study receptor activator for nuclear factor κB ligand (RANKL) in
GCF of periodontitis subjects and healthy subjects. They also examined GCF from subjects with
progressive periodontal destruction. They found a significantly higher level of RANKL in
subjects with periodontitis when compared to controls. Sites with active periodontal disease also
showed significantly higher levels of RANKL than inactive sites [32].
In another study published in the same year, Mogi also used ELISA to investigate
RANKL and osteoprotegerin (OPG) in GCF samples from subjects with various severities of
periodontitis. They found that RANKL was barely expressed in the healthy controls but that its
levels increase significantly with the increase in periodontal disease level. The levels of OPG, on
the other hand, were increased in healthy states and decreased with periodontal disease. It was
found that sites with severe periodontitis had only 12.7% of the OPG level of healthy controls
[33].
Bostanci also examined OPG and RANKL in GCF from healthy, gingivitis, aggressive
periodontitis and chronic periodontitis of healthy and immunosuppressed populations. They
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found a significantly higher RANKL/OPG ratio in all periodontitis groups when compared to
gingivitis and healthy sites [34]. They also examined the effect of non-surgical treatment on the
levels of OPG and RANKL in GCF in a 4-month follow up period. No significant differences
were found between RANKL, OPG and RANKL/OPG ratio at baseline, 2 months, 3 months and
4 months after non-surgical therapy in subjects with chronic and generalized aggressive
periodontitis. This led to the conclusion that although RANKL/OPG ratios may be of value in
chronic periodontitis, it does not have much value in evaluating successful treatment [35].
In 2005, Vernal examined GCF from sixteen subjects with chronic periodontitis and eight
healthy controls. The samples were tested by ELISA for the presence of IL-17. The findings
revealed that the levels of IL-17 was significantly higher in periodontitis subjects as compared to
healthy controls [36].
Silva followed subjects with moderate-severe chronic periodontitis until disease
progression was detected. Two GCF samples were taken from 18 subjects representing an active
and an inactive site. It was found that active sites had significantly higher levels of Receptor
activator for nuclear factor κB ligand (RANKL), IL-1β and MMP-13 when compared to inactive
sites [37].
In a study published in 2010, Offenbacher used an experimental gingivitis model to study
the changes in composition of GCF during inflammation and resolution. Twenty-five subjects
were enrolled in the study. All subjects underwent 1-week hygiene instruction phase, 3-weeks of
experimental gingivitis induction using special acrylic stents that prevent brushing and flossing
of two posterior sextants and then a 4-week resolution phase. GCF samples were collected at the
beginning and end of the hygiene phase, followed by sample collection weekly for 3 weeks. The
subjects were then instructed to use an electric toothbrush for 4 weeks with GCF samples being
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collected at 2 weeks and at the end of the study period. It was found that during the experimental
gingivitis phase, there was a significant increase in IL-1β and IL-1α and a decrease in several
chemokine and MMP levels. The resolution of experimental gingivitis led to the reversal of these
mediators [38]. This shows that inflammatory products in GCF reflect the degree of
inflammation in the gingival tissues.
Leppilahti studied MMP levels in GCF from healthy, gingivitis and chronic periodontitis
subjects. Their aim was to use GCF biomarkers to identify sites showing attachment loss rather
than showing inflammation alone. Fifty-eight samples were analyzed and showed a statistically
significant increase in myeloperoxidase (MPO) and MMP-8 in the periodontitis group as
compared to both gingivitis and periodontally healthy sites. Azurocidin and MMP-14 were
significantly increased in periodontitis sites as compared to health sites and MMP-13 was
significantly higher in periodontitis sites when compared to gingivitis sites. The significant
difference of MPO, MMP-8 and MMP-13 between sites with gingival inflammation without
attachment loss (gingivitis) as compared to sites with attachment loss (periodontitis) may show
the potential of using those biomarkers in diagnosing sites with attachment loss [39].
Most of the published research on the use of GCF biomarkers provides data that
differentiates periodontal disease status but does not give information about potential of
periodontal disease progression. A recently published paper showed the results of a longitudinal
study aiming to evaluate the use of GCF biomarkers in predicting periodontal disease
progression. 83 subjects were divided into 4 groups, healthy, gingivitis, mild chronic
periodontitis and moderate-severe chronic periodontitis. All subjects were monitored for 6
months with GCF sampling done every 2 months. This was followed by a 6-month treatment
phase in which subjects received non-surgical periodontal therapy with GCF sampling done ever
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2 months as well. It was found that subjects in both periodontitis groups showed significant
reduction of MMP-8, MMP-9, C-reactive protein and IL-1β in GCF during the treatment phase
as compared to the non-treatment phase. When GCF biomarkers were compared between
subjects that were found to be periodontally stable and those with periodontal disease
progression it was found that the periodontally-stable subjects had a significantly lower
biomarker level as compared to subjects with disease progression [40]. This shows the potential
usefulness of utilizing GCF testing methods in identifying patients with susceptibility to
periodontal disease progression which may aid in clinical decision making regarding the
appropriate mode of therapy.
GCF testing has been shown to reflect the inflammatory status in periodontal tissues
during various states of health and disease. GCF collection is a simple, minimally invasive
procedure that can be done with little or no discomfort to the patients. Advances in GCF analysis
methods may provide new clinical tools that may allow detection of current periodontal
inflammation status and to detect patients who maybe susceptible to periodontal breakdown.
Additionally, advances in identification of certain biomarker profiles for different disease states
may potentially lead researches to develop host modulatory therapies targeting specific
biomarkers that are present in active diseased states.
Luminex xMAP
The immunological components of GCF and other body fluids have been typically
analyzed using different types of immunoassays such as enzyme-linked immunosorbent assays
(ELISAs). One disadvantage of using ELISA is the need for a separate analysis for every
cytokine which requires a large sample volume in order to perform multiple analyses as well as
cost and time consumption.
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More recently, multiplexing bead-based immunoassays such as the Luminex xMAP
technology have been introduced. These assays allow the analysis of multiple analytes
simultaneously using small sample volumes by utilizing carboxylated polystyrene microspheres
with fluorescent dyes.
Elshal and McCoy reviewed the studies that compared ELISA to multiplex bead based
assays. They concluded that ELISA and multiplex assays do show good correlation between both
methods when variables are minimized and similar protocols are followed [41].
Several recent studies utilized the multiplexing bead-based immunoassays to analyze
different biomarkers in GCF in different situations. One group of researchers collected 4 GCF
samples 1 week post operatively from 15 subjects who underwent periodontal surgery, as well as
4 GCF samples from uninvolved sites in the same subjects. All GCF samples were tested using a
multiplexing bead assay for angiopoietin-1 (Ang-1), vascular endothelial growth-factor (VEGF),
BMP-2, osteoprotegerin (OPG), tissue inhibitor of metalloprotease-1 (TIMP-1), basic fibroblast
growth-factor (bFGF), keratinocyte growth-factor (KGF), and platelet derived growth-factor
(PDGF).

It was found that at 1-week post periodontal surgery, GCF from surgical sites showed

significant increase of Ang-1, VEGF, OPG and TIMP-1. This shows that multiplexing bead
based immunoassays have the ability to provide a profile of biomarkers that characterize events
that occur as part of periodontal wound healing [42].
Thunell also used multiplex fluorescent bead-based immunoassay to compare cytokine
and chemokine levels in GCF samples before and after non-surgical periodontal therapy.
Twenty-two cytokines and chemokine were tested but only sixteen were detected by the assay.
The detected cytokines includes IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-7, IFN-γ and several
chemokines. IL-5, IL-10, IL-12, IL-13, IL-15 and TNF-a were not detected by the assay. At
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initial assessment, levels of IL-1α and IL-1β were higher in periodontally involved sites when
compared to periodontally healthy sites. IL-1α, IL-1β, IL-2, IL-3, IL-6, IL-7, IL-8, IL-12 among
with CCL5, RANTES, eotaxin, macrophage chemotactic protein-1, macrophage inflammatory
protein-1a and interferon-y were significantly reduced in periodontally involved sites after
treatment [43].
Shimada used multiplex fluorescent bead assays to test GCF from patients on periodontal
maintenance for 40 biomarkers including interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL12, IL-13, IL-17A. The assay detected twenty-six biomarkers in all samples. Nine biomarkers,
including MMP-3, IL-1β, IL-21, RANTES, showed significantly higher levels in healthy sites
when compared to diseased sites [44].
A group of researchers published two studies that used multiplexing bead based assays to
analyze GCF in subjects with generalized aggressive periodontitis. Their findings were that
subjects with generalized aggressive periodontitis showed significantly higher levels of IL-1β,
granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-1β/IL-10 ratio. Another
finding of their study was that the different GCF cytokine profiles appear with different
composition of biofilm bacterial complexes[45]. Six months after non-surgical therapy of the
generalized aggressive periodontitis group, GCF samples were collected again and compared to
baseline. It was found that there was significant reduction in GM-CSF, IL-1β and IL-1β/IL- 10
ratio in GCF after non-surgical treatment, with and without the administration of systemic
antibiotics. It was also noted that GCF of IL-6, which is an pro-inflammatory cytokine, was
increased after the same treatment [46].
A more recent study was done on GCF samples from healthy, gingivitis and periodontitis
subjects. Multiplexing bead based analysis was also used to detect GCF levels of interferon
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(IFN)-γ and interleukin (IL)-4, IL-33 and thymic stromal lymphopoietin (TSLP). The significant
finding of this study was that IFN-γ was found to be significantly less in healthy sites in the
periodontitis group than inflamed sites in the gingivitis group. This indicates that IFN-γ can be
used as a site-specific biomarker for inflammation regardless of the patient’s periodontal disease
classification [47].
The previous studies have shown the advantage of using Luminex xMAP in detecting
multiple mediators in a small amount of fluid with less number of assays. Multiplexing assays
seem to have an advantage in analyzing GCF due to the typically limited volume of collected
GCF samples especially in periodontally healthy states.
MFG-E8
Milk Fat Globule-Epidermal Growth Factor-Factor 8 (MFG-E8) or lactadherin is a
secreted glycoprotein found on the milk fat globule membrane [48]. The N-terminal domains of
MFG-E8 are similar in structure to epidermal growth factor (EGF) while the C-terminal domains
are F5/8 type C which resemble coagulation factors V and VIII [49].
The name MFG-E8 came after the identification of epidermal growth factor-like regions
as well as sequences that are similar to coagulation factors V and VII on a protein on the
membrane of milk fat globules secreted by murine mammary epithelial cells [50]. They also
reported the discovery of this same protein in lactating and non-lactating mice though its level
was significantly increased during lactation. Analogous proteins with similar structures were
later identified in bovine and guinea pig milk samples, as well [51-54].
In humans, Larocca group identified a protein that was termed BA46 in the milk fat
globule membrane of subjects who were in the eighth months of pregnancy and underwent
mastectomies due to breast tumors. Their findings have shown that the two C-terminals of BA46
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shared 43% with the sequence of coagulation factor V and 38% with coagulation factor VIII.
They also found that the area of the C-terminal is 60% identical to the same region in the murine
MFG-E8 protein which was described by Stubbs [55].
In 1996, Couto group further studied BA46 and found that it contains a single epidermal
growth factor-like domain which has an arginine-glycine-aspartic acid (RGD) tripeptide
sequence identical to that found previously on one of the epidermal growth factor-like domains
in murine MFG-E8. Their findings suggested that murine MFG-E8 is related to human BA46
even though they do have some differences in structure which maybe related to different
functional requirements of mice vs. Humans [56].
Taylor examined the RGD sequence of BA46 in humans, they found that the RGD
sequence plays a role in cell adhesion by binding to cellular integrin receptors which led to
replacing the name of BA46 to lactadherin [57].
In 1997, Collins group reported the identification of a gene that is homologous to the
gene of murine MFG-E8 in human infant brain DNA which they named huMFG-E8 [58]. They
noted that this gene contains a sequence that is identical to the partial gene sequence of BA46
which was reported by Larocca which suggests that BA46 and huMFG-E8 might be identical
[55, 58].
Further investigations of MFG-E8 have shown that MFG-E8 is not exclusively related to
lactation as was initially thought. It was found in mouse fetal gonadal tissue and that it plays a
role in gonadogenesis [59]. It was also found that it is secreted by macrophages and plays a role
in cell apoptosis [60-62]. The expression of MFG-E8 has also been reported in Langerhans cells,
skin dendritic cells [61], epidermal keratinocytes [63], retina and retinal pigment epithelium [64]
as well as brain microglial cells [65, 66], pericytes [67] and endometrial cells [68, 69].
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Different authors investigated the role of MFG-E8 in different conditions [70]. It was
found to play a role in clearing apoptotic cells, as mentioned previously. This was first reported
by Hanayama, they found that the C-terminal domains of MFG-E8 binds to apoptotic cells while
the RGD motif on the N-terminal binds to phagocytes in preparation to phagocytosis [60, 61].
On the other hand, mice lacking in MFG-E8 showed reduced lymphocyte apoptosis leading to a
pathological autoimmune reaction [71-73] as well as reduced apoptosis of atherosclerotic
plaques in cases of atherosclerosis [74].
MFG-E8 was also found to play a role in Alzheimer's disease [75, 76], systemic lupus
erythematous [77-79], repair of intestinal epithelium [80], stroke [81], asthma [82], pancreatitis
[83], diabetic nephropathy [84], obesity [85], cardiovascular diseases [86] as well as tumor
development [87-89], sepsis and ischemia-reperfusion injuries [90-92] and wound healing [92]
due to increased angiogenesis [67, 93].
In 2014, a paper was published by Abe et al investigating the role of MFG-E8 in
periodontitis in mice. Ligatures were used to induce periodontal inflammation and bone loss [94]
in MFG-E8-/- mice as well as wild-type mice which were used as controls. It was found that the
level of MFG-E8 mRNA was significantly reduced within the first 24 hours. This was followed
by a period of elevation that occurred with the appearance of osteoclasts and multinuclear cells
up to the eighth day. Following that, a period of reduced expression was noted (around day 10)
following the drop in osteoclast count. Further examination of this relationship between
osteoclast levels and MFG-E8 expression revealed that MFG-E8 is expressed by osteoclasts
involved in periodontal bone loss. The role of MFG-E8 in osteoclastogenesis was investigated by
comparing MFG-E8-/- mice with wild-type mice. It was found that osteoclastogenesis was more
efficient in the absence of MFG-E8 and that the application of MFG-E8 to knock-out mice led to
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inhibition of osteoclastogenesis. The application of MFG-E8 to human osteoclast progenitors in
vitro also inhibited osteoclast differentiation and maturation. In vivo, MFG-E8-/- mice
undergoing ligature-induced periodontitis as well as those with naturally occurring periodontitis
showed increased number of osteoclasts and periodontal bone loss as compared to controls
which led to the conclusion that MFG-E8 negatively regulates periodontal bone loss [95].
Recombinant MFG-E8 was injected mice with ligature-induced periodontitis and was
found to inhibit bone loss in both wild-type and MFG-E8-/- groups which may suggest the use of
MFG-E8 as a local therapeutic agent in treatment of periodontitis [95].
In summary, the above-described studies have shown that MFG-E8 is expressed in
various tissues, including the periodontium, and mediates diverse homeostatic functions
including suppression of inflammation, apoptotic cell removal, and regulation of
osteoclastogenesis

AIM
The primary aim of this current research was to detect for the first time the presence of
MFG-E8 in human GCF of subjects with gingivitis, periodontitis and periodontal health and to
determine the role of MFG-E8 as a biomarker to detect periodontal disease activity. The
secondary aim was to test the usefulness of the magnetic multiplexing assays in analyzing
multiple inflammatory mediators in small GCF samples and to relate the MFG-E8 levels to those
of cytokines previously shown to play a role in periodontitis.

MFG-E8 and Periodontal Disease

20

MATERIALS & METHODS
Participants
A group of patients presenting to the Penn Dental Medicine Graduate Periodontal Clinic,
The University of Pennsylvania, Philadelphia, PA were recruited to participate in this crosssectional study from January 2013 to June 2014. The subjects enrolled were grouped as healthy
(H), gingivitis (G), moderate periodontitis (Pm), severe periodontitis (Ps) or localized aggressive
periodontitis (LAP).
The main inclusion criteria were adult subjects with good general health and with at least
10 teeth in the functional dentition excluding third molars and who had never received
periodontal treatment at the time of initial clinical examination. All subjects were required to be
able to read and understand the written consent form. For patients with periodontitis, at least two
quadrants had to involve deep probing depths (PD), clinical attachment loss (CAL) and
detectable radiographic bone loss.
Subjects with the following conditions were excluded:
1.

Smoking, drug or alcohol abuse.

2.

Uncontrolled diabetes.

3.

Previous head and neck radiotherapy.

4.

History of chemotherapy in the previous 12 months.

5.

Immunocompromised subjects or subjects suffering from systemic diseases that
significantly affect the periodontium.

6.

Subjects taking medications known to affect the periodontium (e.g. Phenytoin, calcium
channel blockers, cyclosporine…etc).

7.

Pregnant or lactating females.
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Subjects requiring prophylactic antibiotics.

9.

Subjects taking steroid medications except for acute topical treatment.
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10. Subjects using systemic antibiotics within three months prior to enrollment.
11. Subjects who currently have, or history of (within three months), of the following
diseases: severe cardiovascular, pulmonary or liver diseases, end stage renal disease,
active malignancy, cerebral vascular disease, HIV, TB, hepatitis or other active infectious
diseases.
All subjects who volunteered to participate underwent routine periodontal examination
and were classified according to the Armitage Classification System [4] as either having plaqueinduced

gingivitis, chronic moderate periodontitis, chronic severe periodontitis, localized

aggressive periodontitis or being periodontally healthy.
Subjects with PD < 3 mm, no signs of gingival inflammation, CAL, bleeding on probing
(BOP) or radiographic bone loss were placed in the healthy group. Subjects with PD < 3 mm,
with signs of gingival inflammation or BOP but without CAL or radiographic bone loss were
placed in the gingivitis group. The Moderate Periodontitis group included subjects with CAL of
3-4 mm and moderate radiographic bone loss. Subjects with CAL of 5 mm or more with severe
radiographic bone loss were placed in the severe periodontitis group. Subjects with minimal
amount of gingival inflammation and BOP with CAL and radiographic bone loss that was
limited to the first molars and incisors were placed in the aggressive periodontitis group.
This study was approved by the IRB of the University of Pennsylvania (IRB #817153).
The protocol was explained to the subjects and verbal and written consent was taken in
accordance with the Declaration of Helsinki.
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Sample Collection
All samples were collected by one investigator (F. M.) after reviewing the medical
history and performing clinical and radiographic periodontal examination and establishing a
periodontal diagnosis. PD and CAL were measured at 6 sites for every tooth using a manual
probe (UNC 15, Hu-Friedy, Chicago, IL, USA). Five teeth were selected from each subject with
at least one anterior tooth and two posterior teeth from two different quadrants. The teeth were
dried and isolated with cotton rolls and the samples were obtained from the surface with the
deepest PD. Samples were collected using absorbent paper strips (Periopaper, ProFlow Inc.,
Amityville, NY, USA) which were placed in the selected sites until mild resistance was felt and
kept in place for 30 seconds [96, 97]. Samples with blood or saliva contamination were
discarded. The individual paper strips were subsequently transferred into polypropelene tubes
(Eppendorf, Hamburg, Germany) and were frozen (-80°C) until they were ready to be analyzed.
GCF Samples
A total of 46 subjects were included in the analysis with a total of 230 sites. The site
distribution was as follows: 35 sites (7 subjects) in the Healthy group, 35 sites (7 subjects) in the
Gingivitis group, 60 sites (12 subjects) in the moderate periodontitis group, 70 sites (14 subjects)
in the severe periodontitis group and 30 sites (6 subjects) in the aggressive periodontitis group.
Thirty samples (5 subjects) from the severe periodontitis group were reexamined at reevaluation
appointment after non-surgical periodontal treatment consisting of scaling and root planing and
home care oral hygiene instructions as well as after pocket reduction surgery (Fig 1). At the time
of analysis, the contents of the GCF samples were eluted from the paper strips using phosphate
buffered solution. The level of MFG-E8 and other cytokines were analyzed using Luminex®
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xMAP® multiplexing bead-based immunoassays utilizing magnetic carboxylated polystyrene
microspheres (MagPlexTM).
MFG-E8
MFG-E8 was quantified with a Human Premixed Multi-Analyte Kit (R&D Systems,
Minneapolis, MN, USA). The assay was done according to manufacturer’s instructions. The
diluted magnetic micro particle cocktail was added to the wells of a 96-well magnetic plate.
Samples and standards were added in duplicate to the magnetic beads and incubated for 2 hours
at room temperature with shaking on a plate shaker. The wells were then washed three times
with the supplied Wash Buffer using a magnetic plate holder. Diluted Biotin Antibody Cocktail
was then added to each well and the plate was incubated at room temperature on a plate shaker
for 1 hour. After that, the wash procedure was repeated and diluted Streptavidin-PE was added to
each well. The plate was sealed and incubated for 1 hour on a shaker at room temperature. The
plate was then washed and the microparticles were resuspended in Wash Buffer and incubated on
a shaker for 2 minutes. The plate was then ready to be read by the Milliplex Analyzer (EMD
Millipore, Darmstadt, Germany).
Other Analytes
All samples were also analyzed using HCYTMAG-60K-PX30 Human
Cytokine/Chemokine Magnetic Bead Panel Kit (EMD Millipore, Darmstadt, Germany) to detect
levels of Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-17, TNF-α and TNF-β. The assay was performed
according to the manufacturer’s instructions. The diluted Wash Buffer was added to the wells of
a 96-well plate and the plate was sealed and shaken on a plate shaker for 10 minutes at room
temperature. The plate was then decanted and dried. Standards and Controls were added in
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duplicate to the specified wells followed by PBS. Diluted Assay Buffer was added to the sample
wells followed by the samples which were also added in duplicate. After that, the premixed
beads were added to each well and the plate was sealed and incubated on a plate shaker
overnight at 4°︎ C. At the following day, the plate contents were removed using a magnetic plate
holder to retain the magnetic beads and the plate was washed twice using the Wash Buffer.
Detection antibodies were placed into each well and the plate was sealed and incubated with
agitation on a plate shaker for 1 hour at room temperature. After incubation, StreptavidinPhycoerythrin was added to each well and the plate was incubated with agitation for 30 minutes
at room temperature. The washing procedure was repeated twice. The beads were resuspended
by the addition of Sheath Fluid and agitation for 5 minutes and the plate was run by the Milliplex
Analyzer (EMD Millipore, Darmstadt, Germany).
The samples were also processed a third time using Human Bone Magnetic Bead Panel
(EMD Millipore, Darmstadt, Germany) to detect RANKL, OPG and OPN following the same
procedure as the human cytokine/chemokine kit.
Statistical Analysis
Data were analyzed using Graphpad Prism software. Comparison between groups was
done using Kruskal-Wallis test with Dunn's multiple comparison test for each detected analyte.
Correlation between MFG-E8 and PPD was done using Spearman's rank-order correlation. In the
treatment subgroup, differences after nonsurgical treatment were checked using Wilcoxon signed
ranks test that was repeated for each analyte. p-value of 5% was considered significant.
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RESULTS

The current investigations shows the results of a human GCF analysis in subjects
classified as periodontally healthy, gingivitis, moderate and severe periodontitis as well as
localized aggressive periodontitis. Figure 1 shows the distribution of sites among all groups.
45.65% of the subjects were male and 54.35% were female with a mean age of 53.23 and a
standard deviation of 4.33. The distribution of age and gender among groups can be found in
Table 1. Additionally, table 1 shows the probing pocket depth (PPD) measurements in all groups
at time of initial examination. Table 2 shows the levels of the analytes which were detected in
this study. These include MFG-E8, OPG, RANKL, IL-1α, IL-1β, IL-6 and IL-17A. Table 3.
shows the reduction in (PPD) in the treated severe periodontitis subgroup while Table 4 includes
the cytokine levels of the analyses were detected in the treated severe periodontitis subgroup
(MFG-E8, RANKL, IL-6 and IL-17A).
Figure 2 shows the levels of detected analytes in all subject groups as well as differences
in PPD. No significant difference was found in the levels of MFG-E8 in gingivitis and in health
(p > 0.9999) but the levels in both groups were significantly higher than all periodontitis groups
(p < 0.0001). The moderate periodontitis group showed significantly higher levels of MFG-E8
than both the severe periodontitis group and the aggressive periodontitis group (p < 0.0005) but
no significant difference was found between levels in severe periodontitis and sites with
localized aggressive periodontitis (p > 0.9999). Figure 3 shows the scatter plot of the correlation
between PPD and MFG-E8 in all sites at initial examination. Spearman’s rank correlation
showed significant negative correlation between PPD and GCF MFG-E8 levels (r = -0.7101, p <
0.0001).
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When MFG-E8 was examined after non-surgical and surgical therapy in the severe
periodontitis group, it was found that the level of MFG-E8 in GCF increases with decreasing
probing pocket depths. The level of MFG-E8 was significantly higher after non-surgical therapy
and further increased significantly after surgical therapy as periodontal pockets were eliminated
(p < 0.0001) as seen in Figure 4.
The level of OPG was found to follow a trend similar to MFG-E8 levels. It was found to
be significantly higher in health and gingivitis as compared to periodontitis groups (p < 0.05).
Moderate periodontitis had significantly higher levels of OPG when compared to severe (P =
0.0026) and aggressive periodontitis (p < 0.0001). No significant differences were found
between OPG levels in severe and aggressive periodontitis (p = 0.5604). RANKL, on the other
hand, showed an opposing trend with significantly higher levels in the periodontitis groups as
compared to health and gingivitis (P < 0.0001). No significant differences were found between
the health and gingivitis group (p > 0.9999) or between all three periodontitis groups (p >
0.9999). The level of RANKL was found to be reduced as probing depths were reduced. It was
found to significantly reduce following non-surgical and surgical therapy (p < 0.0001).
The level of IL-1α was also found to be significantly reduced in health and gingivitis as
compared with periodontitis groups (p < 0.0450) with no significant differences among all three
periodontitis groups and no significant difference between health and gingivitis (p > 0.9999). IL1β was significantly lower in health and gingivitis groups as compared to the periodontitis
groups (p < 0.0001). No significant difference was found between health and gingivitis group (p
> 0.9999) or among the periodontitis groups (p < 0.167).
IL-6 was barely detectable in health and gingivitis groups with no significant differences
between both groups but was significantly increased in periodontitis groups (p < 0.0001). The
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moderate periodontitis group had significantly lower levels of IL-6 as compared to the severe
periodontitis group (p = 0.0007) and the localized aggressive periodontitis group (p < 0.0001).
No significant difference was found between the severe and localized aggressive periodontitis
groups (p = 0.8767). IL-6 was also significantly reduced after surgical and non-surgical therapy
(p < 0.0001).
IL-17A was not detected in health and gingivitis but it was detected in all periodontitis
groups with the highest level found in the localized aggressive periodontitis group. The level of
IL-17A in the aggressive periodontitis groups was significantly higher than all other test groups
(p < 0.0001 for healthy, gingivitis and moderate periodontitis. P = 0.0194 for severe
periodontitis). Its level in the severe periodontitis group was significantly higher than the
moderate periodontitis group (p = 0.0003) and both the health and gingivitis groups (p < 0.0001).
Furthermore, the level of IL-17A in the moderate periodontitis group was significantly higher
than the level in health and gingivitis (p < 0.0001). IL-17A was found to be significantly reduced
following non-surgical and surgical therapy (p < 0.0001).

DISCUSSION
The results of the current study have shown that the secreted glycoprotein MFG-E8 can
be detected in human gingival crevicular fluid in different states of health and disease using
magnetic bead-based multiplexing assays. It was also found that the levels of MFG-E8 in human
GCF were higher in cases of health and gingivitis than in periodontal disease, where they are
inversely related to the severity of the disease. It was also shown to be decreased in areas
affected with localized aggressive periodontitis.
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In sites with severe periodontitis that were examined after non-surgical and surgical
periodontal treatment, it was found that total levels of MFG-E8 have increased at the reevaluation visit following non-surgical therapy as compared to the initial values. The levels of
MFG-E8 further increased after surgical therapy which was inversely related to the decrease in
probing pocket depth.
These findings show that the levels of MFG-E8 decrease with increasing inflammation
which is consistent with the findings of several authors in different inflammatory conditions such
as sepsis [98-100], Alzheimer's disease [75, 76], atherosclerosis [74] and others [70]. MFG-E8 is
produced by different cell-types in various tissues including epithelial cells, monocytes,
macrophages, dendritic cells, fibroblasts, osteoblast, and osteoclasts. In general, the expression
of MFG-E8 decreases under inflammatory conditions [70] In this regard, in sepsis, LPS inhibits
the expression of MFG-E8 by macrophages [99]. Similarly, microbial LPS translocated into the
periodontal lesions may inhibit the production of MFG-E8 by macrophages or other cell types
that are commonly seen in the gingival corium subjacent to the epithelium that lines the gingival
crevice. This would result in less MFG-E8 to reach the GCF via the gingival plexus of blood
vessels in the gingival corium, a notion that is consistent with the data of this study. On the other
hand, inflammation-induced osteoclastogenesis is accompanied by increased MFG-E8
expression in the generated osteoclasts [95]. However, since the net effect of inflammation on
MFG-E8 is a decrease of its levels in the GCF, it is possible that the osteoclast-derived MFG-E8
represents a small fraction of its overall production in the periodontium or it is primarily
consumed locally by the osteoclasts in an autocrine manner, as recently shown [95]. Another
possibility might be that the osteoclast-derived proteins may not reach the GCF as readily as
proteins by other cell types that are closer to the gingival crevice or periodontal pockets (for
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instance, passive diffusion of proteins into the crevice should be facilitated by the proximity of
their cellular source). In summary, periodontitis results in decreased levels of MFG-E8 in the
GCF, whereas successful periodontal treatment or periodontal health are associated with
relatively higher GCF levels of MFG-E8. The data of this study therefore suggest that MFG-E8
can be considered as a novel biomarker for periodontal disease.
Receptor activator of nuclear factor-κB ligand (RANKL) which is expressed by
osteoblasts and other stromal cells plays a role in osteoclast differentiation thus leading to
increased bone resorption [101]. Osteoprotegerin (OPG) blocks the activation of osteoclasts by
preventing the activation of RANK on osteoclast progenitor cells by RANKL leading to
decreased bone resorption. The interplay of OPG and RANKL plays a role in regulating
periodontal bone loss [102].The RANKL and OPG findings of the current study are consistent
with what was shown in previous studies in that the level on RANKL is up regulated in human
GCF from periodontitis sites while OPG was down regulated [32-34, 37, 42]. Moreover, the
level of RANKL in the current study was found to be reduced at re-evaluation as compared to
initial values and was further reduced after surgical therapy.
Overall, the investigation of different cytokines which play a role in periodontal disease,
showed that the levels of pro-inflammatory and pro-osteoclastogenic cytokines IL-1α, IL-1β, IL17A, RANKL were up regulated with increasing periodontal disease severity while the levels of
homeostatic molecules, OPG and MFG-E8, were down regulated.
Levels of IL-1 were found to be lower in cases of health and gingivitis and were
increased in moderate periodontitis, severe periodontitis and localized aggressive periodontitis.
That is in agreement with the findings of pervious authors [25-27, 30, 37, 38, 40, 43, 45]. On the
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other hand, another study found a significantly higher levels of IL-1β in healthy sites when
compared to disease sites using a multiplex bead-based assay [44].
IL-6 is a pro-inflammatory cytokine that is release by osteoblastic cells and interacts with
other factors to induce bone resorption [11, 103, 104]. The human GCF levels of IL-6 in the
current study were almost undetected in healthy and gingivitis sites while their levels were
significantly increased in moderate and severe chronic periodontitis as well as in localized
aggressive periodontitis.
Following surgical and non-surgical treatment, it was found that the levels of IL-6 were
reduced. This was also noted by Thunell [43] and Reis [105] where multiplex assays showed a
significant reduction in IL-6 GCF levels in diseased sites after non-surgical therapy. Emingil also
showed similar findings following treatment with Subantimicrobial-dose doxycycline. They
found significant reduction in IL-6 levels up to nine months in sites with probing depths >7 mm
[106]. These findings are inconsistent with the findings of de Lima Oliveira in generalized
aggressive periodontitis cases [46].
IL-17 is a pro-inflammatory cytokine that plays a role in many systemic inflammatory
diseases such as rheumatoid arthritis, asthma and allergic diseases [107]. It exacerbates
periodontal disease by increasing the production of inflammatory mediators from the gingival
fibroblasts [108]. Moreover, IL-17 induces the expression of RANKL by osteoblasts [109]. The
level of IL-17 in the current study was not detected in health and gingivitis sites. It was however
detected in both chronic and aggressive periodontitis sites, consistent with the findings of Vernal
et al [36].
IL-17 was reduced following non-surgical and surgical treatment. Similarly, the study by
Emingil showed significantly lower levels of IL-17 following treatment with scaling and root
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planing with subantimicrobial-dose doxycycline when compared to scaling and root planing
alone.
Although MFG-E8 is an anti-inflammatory protein [70] it is uncertain whether the down
regulation of MFG-E8 contributes to periodontal tissue destruction as a result of defective
regulation of the inflammation. Alternatively, or additionally, the inhibition of MFG-E8
production in periodontitis may result in less efficient phagocytic uptake of apoptotic cells,
thereby contributing to necrosis and enhanced local inflammation. Moreover, Abe et al showed
that MFG-E8 knockout mice had increased osteoclastogenesis leading to increased periodontal
bone loss [95]. Although osteoclasts produce MFG-E8, apparently the level of production is not
sufficient to effectively restrain osteoclastogenesis and pathologic bone resorption in
periodontitis. Therefore, local administration of MFG-E8 may be protective in periodontitis as
suggested by an intervention study in mice, where local microinjection of MFG-E8 protected
mice against periodontal bone loss. Further research is required to confirm if MFG-E8 has
similar protective effects in higher animal species and in humans. This may potentially open the
door for the use of MFG-E8 as a local adjunctive therapy against inflammatory periodontal bone
loss.
In the current study, multiple mediators were detected by analyzing the diluted fluid from
a single paper strip by using 3 different kits. The use of multiplex bead-based immunoassays
enabled the detection of multiple mediators from a single GCF strip. This offers a large
advantage over the use of traditional methods such as ELISA.
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CONCLUSIONS

The results of the current study have shown for the first time the presence of MFG-E8 in
human GCF collected from healthy, gingivitis and periodontitis subjects by using a magnetic
bead-based immunoassay.
The levels of MFG-E8 were negatively related to the level of gingival inflammation and
were found to increase after surgical and non-surgical treatment of periodontal disease. This may
indicate its value as a potential biomarker for periodontal inflammation. This may pave the way
for future research in this field and the potential for development of therapeutic agents.
Multiplexing bead-based immunoassays are capable of detecting multiple analytes in a
single assay leading to findings that are consistent with other studies.
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FIGURES

GCF samples (n = 46 subjects, 230 sites)

Healthy
(n = 7)

Gingivitis
(n = 7)

Chronic
Moderate
Periodontitis
(n = 12)

35 sites

35 sites

60 sites

Non-surgical therapy

4-week re-assessment

Chronic
Severe
Periodontitis
(n = 14)

70 sites

Localized
Aggressive
Periodontitis
(n = 6)

30 sites

30 sites
(5 subjects)

GCF samples

Surgical pocket reduction

4-week post-operative appointment

GCF samples

Figure 1: Flowchart showing distribution of subjects and sites in each group. GCF
testing was done at baseline for all groups. Repeated testing was done after non-surgical
treatment and surgical treatment for a subgroup (30 sites) from the Chronic Severe Periodontitis
group.
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Figure 2: Levels of different analytes and probing pocket depths (PPD) among groups. (A)
MFG-E8, (B) IL-17A, (C) IL-6, (D) RANKL, (E) OPG, (F) IL-1 , (G) IL-1 (H) PPD. Pm:
Moderate Periodontitis, Ps: Severe Periodontitis, LAP: Localized Aggressive Periodontitis, G:
Gingivitis, H: Healthy. * p < 0.05, ** p < 0.0005.
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Figure 3: Scatter plot of correlation between PPD and MFG-E8 in all subjects at initial
examination. Significant negative correlation found between PPD and MFG-E8 (r-coefficient = 0.7101, p-value < 0.0001).
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Figure 4: Change of levels of different analytes and probing pocket depths (PPD) in the
treated severe periodontitis subgroup at initial examination, re-assessment and post-operation.
(A) PPD, (B) MFG-E8, (C) IL-17A, (D) IL-6, (E) RANKL. * p < 0.05, ** p < 0.0005.
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TABLES

Moderate
Periodontitis
Mean
SD
4.13
1.24
53.32
6.28

Severe
Periodontitis
Mean
SD
5.60
1.55
52.35
5.66

Aggressive
Periodontitis
Mean
SD
6.70
1.58
19.32
3.33

Moderate
Periodontitis
Mean
SD
27.00
5.26
120.93 37.50
134.95 23.09
476.01 324.55
531.31 134.73
587.36 150.24
15.93
6.22

Severe
Periodontitis
Mean
SD
12.38
5.88
93.69
29.72
143.73 35.58
525.16 342.00
597.81 133.52
754.01 146.52
24.11
4.85

Aggressive
Periodontitis
Mean
SD
10.60
5.32
75.65
36.69
140.07 32.68
503.67 266.34
651.68 179.22
865.53 170.66
34.20
6.22

Gingivitis
Mean

Healthy

SD

Mean

SD

2.57
0.78
2.09
0.56
PPD
56.78
4.23
49.88
6.57
Age
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Gender
58.3%
41.7%
42.9%
57.1%
33.3%
66.7%
57.1%
42.9%
28.6%
71.4%
(%)
Table 1: Mean probing pocket depth (PPD), age and gender distribution among groups at
time of initial GCF collection.

MFG-E8
OPG
RANKL
IL-1α
IL-1β
IL-6
IL-17A

Gingivitis
Mean
43.82
175.68
48.32
275.45
189.11
102.74
0.03

Healthy

SD
5.67
53.84
20.94
188.81
68.43
36.44
0.03

Mean
41.76
162.10
37.60
191.13
132.43
45.45
0.03

SD
6.77
55.36
13.06
142.58
63.31
18.07
0.03

Table 2: Mean level of MFG-E8, OPG, RANKL, IL-1α, IL-1β, IL-6 and IL-17A among
groups at time of initial GCF collection.
Treatment
Subgroup

Initial

Reevaluation

Post Surgery

Mean
SD
Mean
SD
Mean
SD
PPD
6.03
1.61
3.97
1.07
2.63
0.67
Table 3: Mean probing pocket depth (PPD) in severe periodontitis treatment subgroup at
time of initial GCF collection, 4-week re-evaluation appointment after non-surgical therapy and
4-week postoperative appointment after pocket reduction surgery.
Treatment
Subgroup

Initial

Reevaluation

Post Surgery

Mean
SD
Mean
SD
Mean
SD
MFG-E8
11.31
3.42
17.03
5.47
27.78
7.51
RANKL
149.29
30.27
107.92
23.61
67.67
16.41
IL-6
799.76
138.28
323.20
178.82
152.70
69.42
IL-17A
25.64
5.15
21.64
5.55
12.16
4.93
Table 4: Mean levels of MFG-E8, RANKL, IL-6, IL-17A in severe periodontitis treatment
subgroup at time of initial GCF collection, 4-week re-evaluation appointment after non-surgical
therapy and 4-week postoperative appointment after pocket reduction surgery.
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